Skip links

Immunotherapy to cure chronic hepatitis B virus infections

Project summary

Unsuccessful clearance of hepatitis B virus in chronic patients leads to serious liver problems including liver cancer. Boosting and/or inducing T cell responses against multiple conserved viral antigens with Synthetic Long Peptide immunotherapy may offer a cure. Together Erasmus MC and ISA pharmaceuticals designed and validated the active ingredients.


The aim of this project was to contribute to the development of an immunotherapy for chronic hepatitis B to cure the disease and reduce patient risk to develop end-stage liver disease

More detailed information

Principal Investigator:

Sonja Buschow

Role Erasmus MC:




Project website:

Not available

Funding Agency:

Health Holland